Proteinase-3 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Proteinase-3 (PRTN3; UniProt P24158), expressed in HEK293 cells. Suited for serine protease activity assays, inhibitor IC50 determination, substrate profiling, and antibody validation against the matched Triple Point anti-PR3 antibody (RP-Proteinase3).
Expression system
HEK293
Cat. #
REC-Proteinase3

In stock

SKU
REC-Proteinase3
$498.00

Target Overview

Proteinase-3 (PR-3; gene PRTN3; UniProt P24158) is a 256-amino-acid chymotrypsin-family serine protease (EC 3.4.21.76) stored in the azurophilic granules of neutrophils. This recombinant form is produced in HEK293 mammalian cells, a choice that supports native-like disulfide bonding and glycosylation patterns relevant to the mature, secreted enzyme — features that matter when the protein is used as a substrate-cleavage standard or as an antigen for antibody validation. In activity assays, researchers use PR-3 to measure hydrolysis rates against synthetic chromogenic or fluorogenic peptide substrates, and to determine IC50 values for small-molecule and peptide-based serine protease inhibitors. The protein's well-characterised substrate repertoire — which includes elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV — makes it a practical tool for multi-substrate cleavage profiling by mass spectrometry. PR-3 also participates in cell-signalling contexts studied in neutrophil biology: it cleaves and activates the protease-activated receptor F2RL1/PAR-2, modulating endothelial barrier function during neutrophil transendothelial migration, and it associates with the neutrophil surface marker CD177. Recombinant PR-3 is therefore used as a defined enzymatic reagent in cell-based assays examining PAR-2 cleavage and downstream barrier-function readouts. Researchers validating antibody specificity — for Western blot, immunohistochemistry, or ELISA — can use this recombinant as a positive-control antigen alongside the matched Triple Point Biologics anti-Proteinase-3 antibody (catalog RP-Proteinase3), which has been validated for Western blot against human tissue. The full 256-residue sequence span provides coverage across epitopes targeted by both polyclonal and monoclonal detection reagents.

Background

Proteinase-3 (PR-3; PRTN3) is a neutrophil serine protease first characterised in human myeloid cells and subsequently identified as the principal autoantigen recognised by cytoplasmic anti-neutrophil cytoplasmic antibodies (c-ANCA). The protein circulates between at least two pools in mature neutrophils: a predominant intragranular store within azurophilic (primary) granules and a membrane-associated fraction that becomes surface-exposed upon neutrophil priming. This dual localisation underpins two distinct lines of basic research — intracellular proteolytic processing studies and extracellular receptor-cleavage biology. As a serine protease, PR-3 degrades a broad range of extracellular matrix components in vitro, including elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV. These activities place PR-3 at the intersection of ECM remodelling and neutrophil-mediated tissue injury, and they make recombinant PR-3 a useful positive control in comparative protease panel assays alongside neutrophil elastase (ELANE) and cathepsin G. Published work has also characterised PR-3 as an activator of the protease-activated receptor F2RL1/PAR-2 on endothelial cells, a cleavage event studied in the context of vascular integrity during neutrophil trafficking. PR-3 is most widely studied as a research target in ANCA-associated vasculitis (AAV), where circulating anti-PR3 IgG correlates with disease activity and is used as a diagnostic and research marker. Researchers have used recombinant PR-3 extensively in ELISA-format autoantibody quantification assays and in competition binding experiments to map antigenic epitopes. Beyond AAV, PRTN3 has appeared as a candidate protein biomarker in plasma proteome studies; Huang et al. (2026) identified PRTN3 among novel protein biomarkers for knee osteoarthritis through Mendelian randomisation integrated with plasma proteomics, illustrating how recombinant PR-3 can serve as a calibration standard in biomarker discovery pipelines. PR-3 is also investigated for its role in inflammatory signalling: it triggers neutrophil inflammatory responses upstream of F2RL1/PAR-2 activation through interaction with the adhesion G-protein-coupled receptor ADGRG3. Cell-based assays employing exogenously added recombinant PR-3 have been used to dissect this pathway pharmacologically. Triple Point Biologics has produced validated serine protease and inhibitor antibody reagents since 1994. The matched anti-Proteinase-3 antibody (RP-Proteinase3) was validated for Western blot using human samples; this recombinant provides a defined antigen source for those validation workflows.

Applications

  • Fluorogenic or chromogenic peptide substrate cleavage activity assay (EC 3.4.21.76 serine protease)
  • Inhibitor IC50 determination against small-molecule or peptide-based serine protease inhibitors
  • Substrate profiling by mass spectrometry (ECM substrates: elastin, fibronectin, laminin, collagen types I/III/IV)
  • ELISA-format autoantibody quantification standard for anti-PR3 / c-ANCA detection assays
  • Antibody validation positive control for Western blot using matched anti-Proteinase-3 antibody (RP-Proteinase3)
  • PAR-2 (F2RL1) cleavage and endothelial barrier-function cell-based assay
  • Plasma proteomics calibration standard in biomarker discovery pipelines (e.g., osteoarthritis, vasculitis research cohorts)
  • Comparative protease panel benchmarking alongside ELANE (neutrophil elastase) and cathepsin G

References

  1. Huang W et al. Identification of novel protein biomarkers for knee osteoarthritis by integrating human plasma proteome: evidence from Mendelian randomization and preliminary in vitro investigation. Front Med (Lausanne). 2026. doi:10.3389/fmed.2026.1745114. PMID: 42100251.
  2. Amatya S et al. Machine learning integrated extracellular vesicle proteome analysis for early markers of bronchopulmonary dysplasia. Function (Oxf). 2026. doi:10.1152/function.090.2025. PMID: 41552916.
  3. Zeng H et al. ELANE inhibits the progression of osteosarcoma via suppressing the CXCL12/CXCR4 axis. Mol Cell Biochem. 2026. doi:10.1007/s11010-025-05426-5. PMID: 41489769.
  4. Vidal CMP et al. Stage-Specific Proteomic Profiles in Dental Caries. J Dent Res. 2026. doi:10.1177/00220345251392212. PMID: 41305856.
  5. Kaur S et al. Potential biomarkers in early detection of gastric cancer. Front Pharmacol. 2025. doi:10.3389/fphar.2025.1642927. PMID: 41244835.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight band should I expect for recombinant Proteinase-3 on SDS-PAGE or Western blot?

The mature, processed form of PR-3 (PRTN3; UniProt P24158) runs at approximately 29–32 kDa under reducing SDS-PAGE conditions. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation is present, which typically shifts the apparent MW 2–4 kDa above the theoretical 29 kDa of the 256-aa polypeptide. Expect a diffuse band in the 29–34 kDa range. Under non-reducing conditions, the disulfide-bonded form migrates slightly differently, so always run a reducing control when confirming identity by Western blot.

What processing form of Proteinase-3 is this recombinant — pro-form or mature active enzyme?

This product (REC-Proteinase3) is the mature, active form of PR-3, not the zymogen pro-form. The signal peptide and propeptide sequences have been removed during HEK293 expression and processing, yielding a secreted, catalytically competent serine protease (EC 3.4.21.76). This matters for activity assays: you do not need an exogenous activation step before use. If your experiment requires the zymogen as a negative control, this product is not the appropriate reagent — contact us to discuss options.

What substrates can recombinant Proteinase-3 cleave and which are best for in vitro activity assays?

PR-3 has a broad extracellular matrix substrate repertoire including elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV — useful for multi-substrate MS-based cleavage profiling. For quantitative activity assays, synthetic chromogenic or fluorogenic peptide substrates are preferred. MeOSuc-AAPV-pNA (chromogenic) and MeOSuc-AAPV-AMC (fluorogenic) are well-validated PR-3 substrates; fluorogenic formats typically offer better sensitivity at lower enzyme concentrations. Confirm substrate Km under your specific buffer conditions, as ionic strength influences Km for small peptide substrates.

What buffer conditions work best for Proteinase-3 activity assays and does the storage buffer interfere?

PR-3 is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For activity assays, the storage buffer is generally compatible as a working buffer at ≥10-fold dilution, bringing glycerol below 1% v/v — concentrations above ~5% glycerol can suppress catalytic rates. Most published PR-3 assays use 50–100 mM HEPES or Tris pH 7.4–8.0 with 150 mM NaCl and 0.01–0.05% Tween-20 to reduce surface adsorption. Avoid EDTA; PR-3 is a serine protease, not a metalloprotease, but calcium at low concentrations can stabilize the active site.

What starting concentration of recombinant Proteinase-3 should I use for an IC50 inhibitor assay?

For IC50 determinations against serine protease inhibitors, a common starting point is 1–10 nM PR-3 in assay buffer, used well below the Km of your fluorogenic substrate to satisfy the assumptions of the Cheng-Prusoff equation. Pilot experiments should confirm linearity of substrate hydrolysis over the assay time window at your chosen enzyme concentration. REC-Proteinase3 is supplied at >90% purity by SDS-PAGE and <0.1 EU/µg endotoxin, so background hydrolysis from contaminants is minimal — important when measuring inhibition at low nM enzyme concentrations.

Can I use REC-Proteinase3 as a positive control for Western blot with the matched RP-Proteinase3 antibody?

Yes — this is the recommended use case. REC-Proteinase3 is produced in the same laboratory as the matched rabbit polyclonal antibody (SKU: RP-Proteinase3; see /anti-proteinase-3-rabbit-polyclonal-antibody), and compatibility for Western blot has been validated with this antigen-antibody pair. Load 25–100 ng of REC-Proteinase3 per lane for a clear positive control band at 29–34 kDa. Because both reagents originate from the same source material, this pairing eliminates one of the most common sources of antibody validation ambiguity — antigen mismatch between immunogen and test sample.

How much recombinant Proteinase-3 should I load for Western blot as a positive control lane?

Load 25–100 ng per lane as a starting range with the matched RP-Proteinase3 antibody (SKU: RP-Proteinase3). At 50 ng, the 29–34 kDa band is reliably detected under standard ECL conditions with the antibody diluted 1:1,000–1:5,000. If you are running lysates from PR-3-expressing cells (e.g., neutrophil lysates) alongside, a 50 ng recombinant lane provides a clean, unambiguous size reference. Reduce to 25 ng if your secondary antibody or detection system is particularly sensitive to avoid saturation of the positive control band.

How should I store and handle REC-Proteinase3 to preserve enzymatic activity over time?

Store at −20°C in the supplied single-use aliquots (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol). Avoid repeated freeze-thaw cycles — each cycle can reduce specific activity by measurable increments for serine proteases with multiple disulfide bonds. On the day of use, thaw on ice and dilute directly into pre-warmed assay buffer. For dilutions below ~10 µg/mL, add 0.1% BSA (protease-free) as a carrier to prevent adsorption losses to tube walls. Shelf life is ≥12 months from receipt under recommended storage conditions.

Validation imagery coming soon

Western blot validation figures for REC-Proteinase3 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →